KRT18 and metabolic dysfunction-associated steatotic liver disease: The AT was originally designed for necroinflammatory histological activity diagnosis in chronic hepatitis C and B. According to the observed performance in obese patients, it will be interesting to check the AT performance in patients with other NAFLD risk factors as well as a comparison or combination of cytokeratin 18 for the diagnosis of NASH.